Plasmodium Falciparum Malaria — RBx11160 Phase II Dose Ranging Study RBx/MMV05-06
Citation(s)
A Phase II, Double-Blind, Parallel-Group, Randomized, Dose-Ranging Study Assessing the Antimalarial Activity and Safety of RBx 11160 Administered for 7 Days in Patients With Acute Uncomplicated Plasmodium Falciparum Malaria